- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.3: 8 residues within 4Å:- Chain A: P.205, L.254, N.255, N.369, G.371, V.437, S.438
- Ligands: NAG.16
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.24: 8 residues within 4Å:- Chain E: P.205, L.254, N.255, N.369, G.371, V.437, S.438
- Ligands: NAG.37
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN.45: 8 residues within 4Å:- Chain I: P.205, L.254, N.255, N.369, G.371, V.437, S.438
- Ligands: NAG.58
No protein-ligand interaction detected (PLIP)- 6 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-FUC.5: 4 residues within 4Å:- Chain B: N.107, E.110
- Chain C: S.107
- Ligands: NAG.20
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:N.107, B:E.110
NAG-FUC.6: 4 residues within 4Å:- Chain B: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:N.100, B:S.102
- Hydrophobic interactions: B:Y.127
NAG-FUC.26: 4 residues within 4Å:- Chain F: N.107, E.110
- Chain G: S.107
- Ligands: NAG.41
2 PLIP interactions:2 interactions with chain F- Hydrogen bonds: F:N.107, F:E.110
NAG-FUC.27: 4 residues within 4Å:- Chain F: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:N.100, F:S.102
- Hydrophobic interactions: F:Y.127
NAG-FUC.47: 4 residues within 4Å:- Chain J: N.107, E.110
- Chain K: S.107
- Ligands: NAG.62
2 PLIP interactions:2 interactions with chain J- Hydrogen bonds: J:N.107, J:E.110
NAG-FUC.48: 4 residues within 4Å:- Chain J: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain J- Hydrogen bonds: J:N.100, J:S.102
- Hydrophobic interactions: J:Y.127
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.7: 4 residues within 4Å:- Chain A: E.88, N.89
- Chain B: G.13, S.17
Ligand excluded by PLIPNAG.8: 5 residues within 4Å:- Chain A: T.129, Q.131, S.151, F.152, N.153
Ligand excluded by PLIPNAG.9: 6 residues within 4Å:- Chain A: N.227, T.229, I.265, S.267, I.270, H.344
Ligand excluded by PLIPNAG.10: 1 residues within 4Å:- Chain A: N.138
Ligand excluded by PLIPNAG.11: 1 residues within 4Å:- Chain A: N.347
Ligand excluded by PLIPNAG.12: 3 residues within 4Å:- Chain A: N.269, T.271, N.272
Ligand excluded by PLIPNAG.13: 5 residues within 4Å:- Chain A: Q.355, S.380, N.384
- Ligands: NAG-NAG.1, NAG-NAG.1
Ligand excluded by PLIPNAG.14: 3 residues within 4Å:- Chain A: K.327, N.331, W.387
Ligand excluded by PLIPNAG.15: 6 residues within 4Å:- Chain A: Q.286, N.288, N.324, V.325, S.326, R.435
Ligand excluded by PLIPNAG.16: 6 residues within 4Å:- Chain A: N.255, P.284, V.437, S.438, N.439
- Ligands: NAG-NAG-BMA-MAN.3
Ligand excluded by PLIPNAG.17: 3 residues within 4Å:- Chain A: N.294, I.315, V.433
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain A: V.175, R.185, N.190, T.191
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain A: N.134, G.145
Ligand excluded by PLIPNAG.20: 5 residues within 4Å:- Chain B: S.109, E.110, D.113, N.114
- Ligands: NAG-FUC.5
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain B: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain E: E.88, N.89
- Chain F: G.13, S.17
Ligand excluded by PLIPNAG.29: 5 residues within 4Å:- Chain E: T.129, Q.131, S.151, F.152, N.153
Ligand excluded by PLIPNAG.30: 6 residues within 4Å:- Chain E: N.227, T.229, I.265, S.267, I.270, H.344
Ligand excluded by PLIPNAG.31: 1 residues within 4Å:- Chain E: N.138
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain E: N.347
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain E: N.269, T.271, N.272
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain E: Q.355, S.380, N.384
- Ligands: NAG-NAG.22, NAG-NAG.22
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain E: K.327, N.331, W.387
Ligand excluded by PLIPNAG.36: 6 residues within 4Å:- Chain E: Q.286, N.288, N.324, V.325, S.326, R.435
Ligand excluded by PLIPNAG.37: 6 residues within 4Å:- Chain E: N.255, P.284, V.437, S.438, N.439
- Ligands: NAG-NAG-BMA-MAN.24
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain E: N.294, I.315, V.433
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain E: V.175, R.185, N.190, T.191
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain E: N.134, G.145
Ligand excluded by PLIPNAG.41: 5 residues within 4Å:- Chain F: S.109, E.110, D.113, N.114
- Ligands: NAG-FUC.26
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain F: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.49: 4 residues within 4Å:- Chain I: E.88, N.89
- Chain J: G.13, S.17
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain I: T.129, Q.131, S.151, F.152, N.153
Ligand excluded by PLIPNAG.51: 6 residues within 4Å:- Chain I: N.227, T.229, I.265, S.267, I.270, H.344
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain I: N.138
Ligand excluded by PLIPNAG.53: 1 residues within 4Å:- Chain I: N.347
Ligand excluded by PLIPNAG.54: 3 residues within 4Å:- Chain I: N.269, T.271, N.272
Ligand excluded by PLIPNAG.55: 5 residues within 4Å:- Chain I: Q.355, S.380, N.384
- Ligands: NAG-NAG.43, NAG-NAG.43
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain I: K.327, N.331, W.387
Ligand excluded by PLIPNAG.57: 6 residues within 4Å:- Chain I: Q.286, N.288, N.324, V.325, S.326, R.435
Ligand excluded by PLIPNAG.58: 6 residues within 4Å:- Chain I: N.255, P.284, V.437, S.438, N.439
- Ligands: NAG-NAG-BMA-MAN.45
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain I: N.294, I.315, V.433
Ligand excluded by PLIPNAG.60: 4 residues within 4Å:- Chain I: V.175, R.185, N.190, T.191
Ligand excluded by PLIPNAG.61: 2 residues within 4Å:- Chain I: N.134, G.145
Ligand excluded by PLIPNAG.62: 5 residues within 4Å:- Chain J: S.109, E.110, D.113, N.114
- Ligands: NAG-FUC.47
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain J: E.123, N.126, Y.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Willis, J.R. et al., Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT2 gp120: AEI
HIV Envelope ApexGT2 gp41: BFJ
RM20A3 Fab Heavy Chain: CGK
RM20A3 Fab Light Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
AI
AB
BF
BJ
BC
HG
HK
HD
LH
LL
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Willis, J.R. et al., Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity (2022)
- Release Date
- 2022-09-28
- Peptides
- HIV Envelope ApexGT2 gp120: AEI
HIV Envelope ApexGT2 gp41: BFJ
RM20A3 Fab Heavy Chain: CGK
RM20A3 Fab Light Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
AI
AB
BF
BJ
BC
HG
HK
HD
LH
LL
L